QSAM Biosciences announces the opening of enrollment into the 2nd grouping of participants after completing Cohort 1 in February in its Phase 1 study evaluating CycloSam in the treatment of bone cancer. "We have met all criteria to continue patient enrollment at a higher dose level in the next group of patients," stated Douglas Baum, CEO. "We are pleased with the safety data and early signs of efficacy, and we are now moving forward with three active clinical trial sites to continue to recruit, screen and enroll participants in this important study evaluating the safety and early efficacy of CycloSam(R) in patients with metastatic bone cancer." Baum continued: "With almost $3 million in funding received in our recently completed private placement, and conversion of all of our outstanding convertible notes into common stock, QSAM is in a much stronger position to advance our clinical trials, achieve several important milestones this year, and create a solid foundation for growth and value creation."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on QSAM:
- QSAM Biosciences to Provide Updates on its Clinical Trial at the Emerging Growth Conference on Wednesday, March 22, 2023
- QSAM receives clearance from FDA to expand enrollment criteria in Phase 1 study
- QSAM completes enrollment of initial cohort in Phase 1 study of CycloSam
- QSAM Biosciences recruits EFCC at MU SOM as upcoming trial site for CycloSam
- QSAM Biosciences Recruits the Ellis Fischel Cancer Center at the University of Missouri as Clinical Trial Site to Further Expand and Advance the Study of CycloSam® for Bone Cancer